Ch.3 Specific-item product information summary | JPMA Guide Commentary | Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence

If the comprehensive product information summary paints the full picture of a single drug, leaving nothing out, then the specific-item product information summary is a single cross-section sliced from that picture. An explanation of a feature, a mechanism of action, clinical results, a particular indication or dosage—when the point you want to make is already settled, you build around that one item instead of laying out all sixteen sections. Chapter 3 governs this "narrowed-down" way of building a resource.

Yet narrowing the focus and skipping the foundation are two different things. The first guardrail, placed at the very top of Chapter 3, says exactly this: even a specific-item version must comply with the basic considerations of Chapter 1 and with the relevant item provisions of Chapter 2. Restricting scope does not create freedom from the three disciplines—scientific grounding, the balance of efficacy and safety, and the bounds of approval.

The motive for narrowing is to ease the reader's burden, but that does not mean the editor may pick and choose information at will. What to include may be free, but whether what is included is accurate and non-misleading is judged by the same standard as the comprehensive version. The narrower the page, the more easily a missing context produces a false impression—here the foreword's implication that "the duty not to lie and the duty not to mislead are separate" bites especially hard.

01What counts as a "specific item"

A specific-item product information summary is one whose content is limited to particular items: an explanation of a feature, a mechanism of action, clinical results, an indication, a dosage. Where the comprehensive version runs through everything from the product's identity to its supporting references and revision date, this one fixes on a single theme and writes carefully only around it.

In character it is close to a subset of the comprehensive version. Precisely for that reason, care is needed so that showing only a part does not mislead about the whole. A resource that extracts only clinical results, with a thin treatment of safety, can leave an impression skewed toward efficacy. Many of Chapter 3's provisions exist to curb this "bias born of partial presentation."

Relationship with Chapters 1 and 2

The specific-item version is not a separate, independent line of resource; it lives inside the same normative system as the comprehensive version. It must satisfy Chapter 1 (the foundation that applies to all resources) and also follow the Chapter 2 item provisions corresponding to the items it handles. If it carries clinical results, for example, the requirements imposed by Chapter 2's clinical-results item—stating the trial design, distinguishing confirmatory analyses from nominal p-values, attaching the source—remain in force unchanged.

02Mandatory items—the core you cannot drop even when narrowing

Narrowing the items does not license deleting information essential for safe use. Chapter 3 sets out the mandatory items to be carried whatever the theme. The key point is that the information identifying the product, the substance of the approval, and the framework of safety are all present together.

Information identifying the product—classification number, therapeutic category name, regulatory class, name, and whether it is listed in the drug price standard
The most important safety frame—warnings and contraindications
The product's makeup—composition and properties
The substance of the approval—indications (with related precautions) and dosage and administration (with related precautions)
The system of precautions for use—important basic precautions, precautions for patients with specific backgrounds, interactions, adverse reactions, effects on clinical test results, overdose, precautions concerning application, and other precautions
Practical information—precautions on handling, packaging, related information
Accountability and version—the marketing authorization holder and the date of preparation or revision

Reading the order, it begins with the product's identity, brackets the bounds of approval, passes through the system of precautions, and closes with "who made it" and "which version." The same design philosophy as the comprehensive version—closing with the grounds and the version so that later verification is structurally guaranteed—runs through the condensed version too.

Conditions when consolidating mandatory items into the DI

The mandatory items may also be consolidated together in the product information (DI) section. This is a practical accommodation for organizing the page, but it is not unconditional. When consolidated, the resource must also state that "the details are to be found in the package insert" and that "attention should be paid to revisions of the package insert."

These two co-statements are required because they implement the positioning stated in the foreword: that the product information summary supplements the package insert. The resource is not the original. The authoritative text of the approval is the package insert, and that text keeps being revised. So the resource bears a duty to make plain to the reader both that it is merely a digest and that the authoritative text it points to keeps moving.

Type in the DI section, figures and tables aside, must be at least 6 points. This is a floor that prevents "counting as carried" mandatory information that has been compressed to an unreadable size.

03The cover—placing the most important information in the first field of view

The cover's items are handled as in the comprehensive version. The cover is the face of the resource, the surface a reader sees first. For that very reason, its appearance is regulated down to detail so that the most important safety information falls within the first field of view.

How warnings and contraindications are shown

Warnings and contraindications are placed on the cover in gothic type of at least 10 points, clearly. Specifying the typeface and point size is the foreword's "convey accurately, without misleading" translated into physical layout. Merely being written is not enough. Unless it enters the eye first and reliably, the safety information has not been conveyed.

The unified mark in the first six months after launch

A new drug subject to early post-marketing phase vigilance carries the unified mark on its cover for the first six months after launch. In the period soon after reaching the market, the safety profile is still accumulating, and the mark signals that uncertainty to the reader.

04Safety and the honesty of data

Precisely because the narrowed-down form often pushes clinical results or features to the front, clear guardrails are placed on how safety is handled.

The type size of safety

Statements about safety are set in type the same size as, or larger than, the body text for efficacy. Efficacy must not outweigh safety in the physical size of the type—the asymmetric care that "if you speak of efficacy, you must show safety at least as prominently" is again implemented here as layout.

Even when the original paper carries no safety description, the safety section must not be left blank. State both that "the paper in question carries no safety description" and that the reader should "refer to the package insert." The absence of data and the freedom not to convey safety are not the same. The requirement is to show the very gap in information in a form visible to the reader.

How primary endpoints are shown

In a trial that set a primary endpoint, its result is set in the same typeface and the same type size as the result of the secondary endpoints. At a glance this is a matter of technical formatting, but the aim is to shut down impression management. If typeface or size differed between primary and secondary, results that should not be read as ranked could be ranked for the reader by visual emphasis.

The thrust of the rule actually runs the other way. Rather than dressing up a confirmatory primary endpoint larger than necessary, setting it at "the same weight" as an exploratory secondary endpoint makes both read as elements within a pre-specified analysis plan. It translates into layout the statistical discipline that clinical value must not be spoken through the size of the type.

05Isolating reference information

Reference information—results obtained secondarily within the approved range, or pharmacological actions that underpin an indication—is constrained in placement and in volume so that it does not blend, in the reader's mind, with the genuine approval information. Chapter 3 guards this distinction with three concrete fences.

Aspect	Approval information (indications, dosage, principal results)	Reference information
What may be carried	Indications, dosage within the approved range, and the principal results supporting them	Limited to secondary results of approved indications, or pharmacology underpinning the indication
Placement	May appear on the cover and the pages following it	Not placed on the cover or the pages following it
Volume limit	No limit (must satisfy the mandatory items)	No more than one quarter of the page, excluding the cover and DI
Supervisor's comment	—	None attached

Why it is kept off the cover

Reference information is barred from the cover and the pages following it because the first information a reader meets must be the authoritative text of the approval. If a secondary result or a pharmacological action of unclear relevance adorns the opening, it gets misread as the product's principal selling point. The opening is a place for approval information; reference information goes behind it, in a clearly distinguished form.

Why the limit is one quarter

Holding the volume to within a quarter of the page, excluding the cover and DI, prevents the resource as a whole from being padded out with reference information so that "reinforcing material" overshadows the facts of the approval. Reference information is a supporting role to the end and cannot become the lead on the page—the volume cap guarantees that division of roles.

Why no supervisor's comment

Attaching a supervisor's comment to reference information would lend a third party's authority to what is merely a supplement, giving it weight equal to or greater than the approval information. Reference information must not be promoted by borrowed authority—the ban on comments is the fence for that.

In closing

The specific-item product information summary is not "a resource you are allowed to make short" but "a resource whose foundation cannot be removed even when the focus is narrowed." Building on Chapters 1 and 2, never dropping the mandatory items, and—if consolidating into the DI—co-stating the reference to the package insert and the attention to its revisions: all of these flow from the foreword's spirit, that the resource stands in a position supplementing the authoritative text of the approval.

The rules on appearance (gothic 10 points for warnings and contraindications, the type size of safety, the identical typeface for primary and secondary) are not trivial formatting. The accuracy of information is decided not only by what is written but by how it is shown. And the isolation of reference information—placement, volume, the ban on comments—is a triple fence so that reinforcing material does not erode the facts of the approval. To remain non-misleading even after narrowing down: that is the destination of Chapter 3.

Case studies — the "it isn't written, so…" mindset, and how each lands

Chapter 3's focused-item format is a material that may narrow its scope — not one that may drop its foundations. The cases below dissect the temptation to read "we focused the content" as "the rules no longer fully apply," targeting the three layers of discipline: mandatory items, DI section font-size minimums, and the placement constraints on reference information.

GRAY 1 — Straying from the spirit (untouched by the wording, but against the foreword's spirit)

The scheme: "I produced a clinical-data-focused material and recorded both primary and secondary endpoints in the same font and point size. But I placed the primary endpoint figure large and centred on the page, with secondary results in smaller frames around the edges. The font rule is satisfied."

Verdict: The rule requires primary and secondary endpoint results to appear in the same font and same point size; its purpose is to prevent page design from creating a perceived hierarchy of importance between the two. Placing the primary figure prominently at the centre concentrates attention and memory on it regardless of matching fonts. "Font matches" does not satisfy the foreword's mandate to implement balance at the layout level. Directing the reader's gaze through position and area is a layout manipulation that circumvents the font rule.

GRAY 2 — Exploiting the gap (deliberately working a loophole to invite misreading)

The scheme: "Reference information must not appear on 'the cover and the pages that follow it.' The inside of the front cover is technically a separate page in binding terms, and what counts as 'following' the cover is ambiguous. Putting reference information there places it in the first spread a reader sees — high-impact placement."

Verdict: The reason the rule excludes the cover and its following pages from reference information is to reserve the first field of view for approved information. The inside of the front cover is the first surface a reader sees upon opening, and is the paradigm case of "the page that follows the cover." Whether it constitutes an independent page in binding terminology is irrelevant to the rule's purpose, which concerns the sequence in which information is encountered. Placing reference information in the opening spread directly contradicts that purpose.

GRAY 3 — Violating higher norms (arguably "not in the text," yet almost certainly out under the PMD Act, Fair Advertising Standards, and the JPMA Code)

The scheme: "I matched the safety font size to the efficacy font size. But since the cited paper contained no safety data, I just wrote a single line saying 'no safety information was provided in this publication' and omitted the instruction to refer to the package insert. I told the reader about the absence — that counts."

Verdict: The rule requires two things together: a statement that the paper contains no safety information, and a direction to consult the electronic package insert. Stating the absence alone leaves the reader with no path to safety information. The Fair Advertising Standards require that safety information be provided in an accessible manner; a section that goes no further than "data absent" risks being read as "no safety concern." The two-part requirement is an indivisible pair — omitting either half fails the obligation.

BLACK — Breaching the explicit text (a plain violation of the provision itself)

The scheme: "I consolidated all mandatory items into the DI section, but the content was too dense to fit in the space, so I set the DI text at 5 point. The 6-point threshold must be a recommendation, not a hard floor."

Verdict: Chapter 3 states explicitly: "The text of the DI section, excluding figures and tables, must be set at 6 point or larger." This is a minimum requirement, not guidance. 5-point text falls below the stated threshold and is a direct violation of the provision designed to prevent compressing mandatory information to an unreadable size and claiming it has been included. Space constraints do not change the condition. The material must be revised to 6 point or larger; if it does not fit, the layout must be redesigned.

Improper intent by implication — three scopes of "insinuating" without stating it

A specific-item product information summary selects a subset of the 16 standard items and presents only those. The very structure — "narrowing down" — creates a temptation to read it as a licence to omit. The guidelines make the correct reading explicit: narrowing limits which items appear, not the rules that govern any item that does appear. The three patterns below show how the narrowed-format structure is used as cover to exclude safety information in effect.

Implication 1 — Local: carried in a single word or sentence

How it is built: "The cover title of the specific-item summary reads: 'Product Information Summary on Efficacy.'"

Intent that can be read: The limiting phrase "on Efficacy" in the title implies that this document handles efficacy and that safety falls outside its scope. From this single phrase, the reasoning follows: because the material addresses only efficacy, the absence of safety content is a natural consequence of the format.

Verdict: A specific-item summary cannot escape Chapter 1's requirements. The obligation to present safety information in type at least as large as efficacy information applies to the narrowed format without reduction. The moment efficacy data appear in the document, the obligation to include safety data is triggered. The title phrase does not alter the scope of that obligation. The correct approach is to label the document accurately as a specific-item summary and to include both efficacy and safety.

Implication 2 — Adjacent: read across neighboring clauses

How it is built: "This material is a specific-item product information summary focused on efficacy (for safety details, please refer to the electronic package insert). The safety profile in this patient population has been confirmed in clinical trials." — these two sentences appear together at the opening.

Intent that can be read: The first sentence appears to discharge the safety-inclusion obligation by pointing to the package insert, then the second immediately enters a positive safety claim. The formal disclaimer (refer to the package insert) is used as cover for a safety assurance placed in the very next sentence.

Verdict: Directing readers to the package insert does not substitute for the in-document safety obligation. Furthermore, Chapter 2 prohibits emphasis on or assurance of safety; "the safety profile has been confirmed" constitutes such an assurance. The two-sentence pattern violates two separate requirements simultaneously. The correct approach is to present actual safety data — adverse event incidence, relevant warnings — in the document body at a size equal to or greater than the efficacy section, and to omit any assurance of safety.

Implication 3 — Whole-context: arising from the document as a whole

How it is built: "The opening states: 'This material provides key efficacy information needed for prescribing decisions.' Every page presents only clinical data and pharmacokinetics. No page contains any safety content."

Intent that can be read: Equating "what is needed for prescribing decisions" with "efficacy key points" frames safety information as unnecessary for prescribing. Its total absence across every page is established as a deliberate editorial design before the reader reaches any specific claim.

Verdict: Prescribing decisions require safety information; defining "necessary for prescribing" as "efficacy only" inverts the balance requirement at the level of the document's governing premise. Chapter 1 requires that safety appear at equal weight when efficacy is shown. The specific-item format does not cancel this obligation when efficacy data are presented. A document designed entirely around the exclusion of safety fails the balance requirement at every page. The correct approach is to give safety information equal standing in the document design, regardless of how the document's purpose is framed.